# Clinical Features and Prognosis of Cervical Esophageal Cancer

## TL;DR

This study compares cervical esophageal cancer with other types, finding that cervical tumors are more severe but respond similarly to treatment.

## Contribution

The study provides new insights into the clinical features and treatment outcomes of cervical esophageal cancer.

## Key findings

- Cervical ESCC patients were older and had worse tumor differentiation and higher T stages.
- Outcomes were similar between cervical and non-cervical ESCC when treated with definitive chemoradiotherapy.
- There was no significant difference in lymph node or distant metastasis between the two groups.

## Abstract

Background: This study aimed to analyze the clinical features and prognosis of cervical esophageal squamous cell carcinoma (ESCC) compared to ESCC more inferiorly in the esophagus. Methods: Medical records of patients with ESCC between December 2008 and December 2024 were retrospectively reviewed. A total of 497 patients with ESCC were included and divided into cervical (n = 32) and non-cervical (n = 465) groups. Clinical features and survival according to treatment were compared between the two groups. Results: Patients with cervical ESCC were older (median age 73 years vs. 67 years, p = 0.047) with a higher proportion of females (18.7% vs. 10.1%, p = 0.133) than patients with non-cervical ESCC. Cervical ESCC had worse differentiation (34.4% vs. 19.6%, p = 0.049 in the rate of poorly differentiated carcinoma) and higher T stage (6.2% vs. 37.2%, p = 0.003 in T1; 28.1% vs. 4.7%, p < 0.001 in T4) than non-cervical ESCC. There was no difference in lymph node metastasis (65.6% vs. 54.6%, p = 0.229) or distant metastasis (15.6% vs. 15.5%, p = 0.983) between the two groups. Overall survival was lower in the cervical group (hazard ratio [HR], 1.51; 95% confidence interval [CI], 0.96–2.40; p = 0.076). When comparing outcomes of patients who underwent definitive chemoradiotherapy, the complete response rate (63.6% vs. 53.4%, p = 0.340) and survival (HR, 1.01; 95% CI, 0.51–1.99; p = 0.973) were similar between the two groups. Conclusions: Although cervical ESCC had a poor prognosis due to its higher T-stage and worse differentiation compared to other locations, outcomes were similar when treated with definitive chemoradiotherapy.